• Home News POTENTIAL REPURPOSING OF FAVIPIRAVIR IN COVID-19 OUTBREAK BASED ON CURRENT EVIDENCE

POTENTIAL REPURPOSING OF FAVIPIRAVIR IN COVID-19 OUTBREAK BASED ON CURRENT EVIDENCE

Posted 23 Oct-2020 01:57 PM by Pro | 1839

We at Genpro Research are conducting analysis on the available research data to recognize the molecules that can be repurposed for COVID-19. As part of this exercise, we identified Favipiravir (Favilavir) as early as Feb-2020. However, unavailability of results from >85% of favipiravir completed clinical trials in registries or in published papers prevented the pooling of data and conducting a meta-analysis to generate conclusive evidence to support a recommendation of Favipiravir use in COVID-19 or know about its safety and efficacy profile. Our VP of Medical Writing, Dr. Kapil M Khambholja published an article in Elsevier's journal to share the observations to the scientific fraternity. The article is titled as œPotential repurposing of Favipiravir in COVID-19 outbreak based on current evidence and can be located at https://doi.org/10.1016/j.tmaid.2020.101710

Dr. Kapil & co-author Dr. Asudani from the University of California, San Diego, USA summarise key points: œMany such promising drugs can be overlooked by scientific panels due to lack of conclusive evidence, especially when expedited repurposing and approval of therapeutics effective in pandemic is needed. We might already have available drugs with significant potential to curb the spread of new Coronavirus and prevent significant morbidity and mortality. The authors conclude that reporting of all available results and evidence from past clinical trials, even if it indicates failure of interventions evaluated, must be ensured for enabling timely repurposing of effective therapeutics based on scientific evidence from past. Absence of published results from past clinical trials not only hinders future evidence-based research but also may violate data transparency norms set by several countries and undermine ethical standards overall. Through this mini review evaluating prior and ongoing clinical trials on Favipiravir, it is urged that the findings of these trials be made available and disseminated to the scientific community so that it may facilitate timely and crucial understanding of Favipiravir as a potential therapeutic option during COVID-19 pandemic

Tags:

Clinical Data visualization tools, clinical trial data management, clinical biostatistics services, Statistical Programming services, Regulatory & Medical Writing Services, Affordable Press Release Network, Affordable Press Release Services, Affordable Press Release Website, Affordable Press Release Distribution Site, Free Press Release Site

Company Information

Company Name Contact Person Contact Number Email Id Website Address
Gen Pro Research

Other Health Related Press Release News

NutraBio Supports First Responders Nationwide Free

NutraBio Labs Inc., a dietary supplement manufacturer in Middlesex, NJ, has dedicated part of its GMP manufacturing facility to making an im...Read More


Collecting personal health for clinical decisions Advice for Product Managers Free

Taking temperature and tracking blood oxygen levels helps individuals with COVID-19 monitor their condition at home or in isolation at the clinic to g...Read More


Guy Fieri Serves up Meals and Thank-Yous to Hospital Staff Free

Celebrity chef Guy Fieri?s bright smile and goatee may have been tucked behind a cloth mask while serving meals to medical staff at Sutter Santa ...Read More


As People Lose Jobs Due to the Coronavirus Crisis and Enroll in Medicaid, Survey Finds States Anticipate Medicaid Budget Shortfalls Free

Many states that shared budget projections in response to a new KFF survey of state Medicaid officials report that they expect to see Medica...Read More


Impact of COVID-19 on Consumer Behavior in the US and Brazil Free

The "Impact on Consumer Behavior in the Americas: COVID-19 Survey Snapshot" report has been added to ResearchAndMarkets.com's offering.The publisher i...Read More